Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Diseases

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 47 articles:
HTML format



Single Articles


    March 2021
  1. WILLIAMS R, Alessi C, Alexander G, Allison M, et al
    New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK.
    Lancet. 2021 Mar 10. pii: S0140-6736(20)32396.
    PubMed     Abstract available


    October 2020
  2. KRONLAGE C, Hardmeier M, Bally S, Scholz MC, et al
    Muscle stiffness, gait instability, and liver cirrhosis in Wilson's disease.
    Lancet. 2020;396:990.
    PubMed    


    July 2020
  3. LIN AJ, Baranski T, Chaterjee D, Chapman W, et al
    Androgen-receptor-positive hepatocellular carcinoma in a transgender teenager taking exogenous testosterone.
    Lancet. 2020;396:198.
    PubMed    


    June 2020
  4. STRAVITZ RT, Lee WM
    Acute liver failure - Authors' reply.
    Lancet. 2020;395:1833-1834.
    PubMed    


  5. VENTO S, Cainelli F
    Acute liver failure.
    Lancet. 2020;395:1833.
    PubMed    


  6. AHMED MA, Abdelnabi M, Almaghraby A, Elkafrawy FR, et al
    Neuropathy, encephalopathy, status epilepticus, and acute intermittent porphyria.
    Lancet. 2020;395:e101.
    PubMed    


    March 2020
  7. FORD J
    Ursodeoxycholic acid for adverse perinatal outcomes.
    Lancet. 2020;395:780.
    PubMed    


    January 2020
  8. WILLIAMS R, Aithal G, Alexander GJ, Allison M, et al
    Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK.
    Lancet. 2020;395:226-239.
    PubMed     Abstract available


    December 2019
  9. ESLAM M, Alvani R, Shiha G
    Obeticholic acid: towards first approval for NASH.
    Lancet. 2019;394:2131-2133.
    PubMed    


  10. YOUNOSSI ZM, Ratziu V, Loomba R, Rinella M, et al
    Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)33041.
    PubMed     Abstract available


    November 2019
  11. RATZIU V
    Improving NASH with a little help from thyromimetics.
    Lancet. 2019;394:1970-1972.
    PubMed    


  12. HARRISON SA, Bashir MR, Guy CD, Zhou R, et al
    Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2019 Nov 11. pii: S0140-6736(19)32517.
    PubMed     Abstract available


    September 2019
  13. ZHOU M, Wang H, Zeng X, Yin P, et al
    Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2019;394:1145-1158.
    PubMed     Abstract available


  14. STRAVITZ RT, Lee WM
    Acute liver failure.
    Lancet. 2019;394:869-881.
    PubMed     Abstract available


    August 2019
  15. LOW ESL, Patwala K, Apostolov R
    Dyspnoea, clubbing, cirrhosis, and bubbles in both sides of the heart suggests hepatopulmonary syndrome.
    Lancet. 2019;394:510.
    PubMed    


  16. CHAPPELL LC, Bell JL, Smith A, Linsell L, et al
    Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial.
    Lancet. 2019 Aug 1. pii: S0140-6736(19)31270.
    PubMed     Abstract available


  17. MARSCHALL HU
    Ursodeoxycholic acid for intrahepatic cholestasis in pregnancy.
    Lancet. 2019 Aug 1. pii: S0140-6736(19)31607.
    PubMed    


    July 2019
  18. VIVANTI AJ, Voican C, De Luca D, Benachi A, et al
    Intrahepatic cholestasis: suggested future investigations.
    Lancet. 2019 Jul 1. pii: S0140-6736(19)31391.
    PubMed    


  19. OVADIA C, Chappell LC, Williamson C
    Intrahepatic cholestasis: suggested future investigations - Authors' reply.
    Lancet. 2019 Jul 1. pii: S0140-6736(19)31389.
    PubMed    


    June 2019
  20. HAWKINS P, Logan PM, Reeves EP, McElvaney NG, et al
    Pneumothorax and lung cysts: a family affair.
    Lancet. 2019;393:2635.
    PubMed    


    March 2019
  21. LEVY S, Samuel D
    Prevention of decompensation in cirrhosis: a new youth for beta blockers.
    Lancet. 2019 Mar 22. pii: S0140-6736(19)30736.
    PubMed    


  22. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet. 2019 Mar 22. pii: S0140-6736(18)31875.
    PubMed     Abstract available


  23. JANUSZEWICZ W, Corrie P, Liu H, Chan J, et al
    A sinister black finding in the stomach.
    Lancet. 2019;393:1149.
    PubMed    


  24. CORNEC-LE GALL E, Alam A, Perrone RD
    Autosomal dominant polycystic kidney disease.
    Lancet. 2019;393:919-935.
    PubMed     Abstract available


    February 2019
  25. OVADIA C, Seed PT, Sklavounos A, Geenes V, et al
    Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses.
    Lancet. 2019 Feb 14. pii: S0140-6736(18)31877.
    PubMed     Abstract available


  26. PALMER KR, Xiaohua L, Mol BW
    Management of intrahepatic cholestasis in pregnancy.
    Lancet. 2019 Feb 14. pii: S0140-6736(18)32323.
    PubMed    


    January 2019
  27. BRAILLON A
    Laennec's cirrhosis.
    Lancet. 2019;393:131-132.
    PubMed    


    December 2018
  28. WONG VWS, Adams LA
    Fibroblast growth factor 21 for non-alcoholic steatohepatitis.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)32165.
    PubMed    


  29. SANYAL A, Charles ED, Neuschwander-Tetri BA, Loomba R, et al
    Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)31785.
    PubMed     Abstract available


  30. SARGENT J, Horton R
    Transforming the landscape of liver disease in the UK.
    Lancet. 2018;392:2332-2333.
    PubMed    


    November 2018
  31. CARACENI P, Roncadori A, Bernardi M
    Questions in the design of ANSWER - Authors' reply.
    Lancet. 2018;392:1623-1624.
    PubMed    


  32. ROWE IA, Parker R
    Questions in the design of ANSWER.
    Lancet. 2018;392:1623.
    PubMed    


    August 2018
  33. MANNS MP, Burra P, Sargent J, Horton R, et al
    The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities.
    Lancet. 2018;392:621-622.
    PubMed    


    July 2018
  34. BARNETT R
    Liver cirrhosis.
    Lancet. 2018;392:275.
    PubMed    


    May 2018
  35. GARCIA-TSAO G
    Long-term albumin in cirrhosis: is it the ANSWER?
    Lancet. 2018 May 31. pii: S0140-6736(18)30948.
    PubMed    


  36. CARACENI P, Riggio O, Angeli P, Alessandria C, et al
    Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
    Lancet. 2018 May 31. pii: S0140-6736(18)30840.
    PubMed     Abstract available


    March 2018
  37. CHARLTON M
    FGF-19 agonism for NASH: a short study of a long disease.
    Lancet. 2018;391:1124-1126.
    PubMed    


  38. REIG M, Bruix J
    Lenvatinib: can a non-inferiority trial change clinical practice?
    Lancet. 2018;391:1123-1124.
    PubMed    


  39. HARRISON SA, Rinella ME, Abdelmalek MF, Trotter JF, et al
    NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2018 Mar 5. pii: S0140-6736(18)30474.
    PubMed     Abstract available


    February 2018
  40. KUDO M, Finn RS, Qin S, Han KH, et al
    Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Lancet. 2018 Feb 9. pii: S0140-6736(18)30207.
    PubMed     Abstract available


    January 2018
  41. PATTEN DA, Shetty S
    Chronic liver disease: scavenger hunt for novel therapies.
    Lancet. 2018;391:104-105.
    PubMed    


  42. FORNER A, Reig M, Bruix J
    Hepatocellular carcinoma.
    Lancet. 2018 Jan 4. pii: S0140-6736(18)30010.
    PubMed     Abstract available


    August 2017
  43. SCHACHTER J, Ribas A, Long GV, Arance A, et al
    Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31601.
    PubMed     Abstract available


    April 2017
  44. WORNS MA, Galle PR
    Immune oncology in hepatocellular carcinoma-hype and hope.
    Lancet. 2017 Apr 20. pii: S0140-6736(17)31044.
    PubMed    


  45. EL-KHOUEIRY AB, Sangro B, Yau T, Crocenzi TS, et al
    Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    Lancet. 2017 Apr 20. pii: S0140-6736(17)31046.
    PubMed     Abstract available


    February 2017
  46. HEGADE VS, Kendrick SF, Dobbins RL, Miller SR, et al
    Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Lancet. 2017 Feb 7. pii: S0140-6736(17)30319.
    PubMed     Abstract available


    November 2016
  47. KIRBY T
    Profile: The Kirby Institute celebrates 30 years.
    Lancet. 2016;388:2466.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: